country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99683

Copy Link Print Information

Ladiratuzumab vedotin

(Synonyms: SGN-LIV1A)

Customer Review

Based on 1 Customer Validation

Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC₅₀: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer.

For research use only. We do not sell to patients.

Purity: 99.57%
CAS No.: 1629760-29-7
Molecular Weight:152224 (average)

Storage:

-80°C, protect from light

Ladiratuzumab vedotin Chemical Structure

CAS No.: 1629760-29-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Ladiratuzumab vedotin (LIV-1+ cells) activates the ER stress response via the activation of ATF6 and phosphorylation of IRE1 and eIF2a^[3].
Ladiratuzumab vedotin (LIV-1+ cells) releases ATP and HMGB1 into the supernatant (hallmarks of ICD^[3].
Ladiratuzumab vedotin (0-100 ng/mL) shows cytotoxic activity against MCF-7 cell line^[4].
Ladiratuzumab vedotin (1 μg/mL, 24 h) internalizes, traffics to the lysosome, and disrupts the microtubule network in MCF-7 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

MCF-7
Concentration:

0-100 ng/mL
Incubation Time:

96 h
Result:

Inhibited cell viability with an EC₅₀ value of 6.3 ng/mL.

In Vivo

Ladiratuzumab vedotin (3 mg/kg, i.p., every 4 days) results tumor regression in MCF-7 breast cancer cell xenograft model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MCF-7 breast cancer cell xenograft model^[4]
Dosage:

3 mg/kg
Administration:

i.p., every 4 days
Result:

Delayed tumor growth.

Animal Model:

BALB/C mice (PK assay)^[4]
Dosage:

3 mg/kg
Administration:

i.v., single
Result:

Showed a terminal half-life of 6.8 days.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1629760-29-7
Appearance Liquid
Molecular Weight 152224 (average)
Color Colorless to light yellow
SMILES

[Ladiratuzumab vedotin]
Synonyms

SGN-LIV1A
Shipping

Shipping with dry ice.
Storage

-80°C, protect from light

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (269 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Rizzo A, et al. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs. 2022 Jun;31(6):495-498. [Content Brief]

[2]. Jane Lowe Meisel, et al. Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress). Journal of Clinical Oncology. 2022 40:16_suppl, TPS1127-TPS1127.

[3]. Anthony T. Cao, et al. Abstract 2742: Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Cancer Res (2018) 78 (13_Supplement): 2742.

[4]. Sussman D, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote